A gene-protein assay for human epidermal growth factor receptor 2 (HER2): brightfield tricolor visualization of HER2 protein, the HER2 gene, and chromosome 17 centromere (CEN17) in formalin-fixed, paraffin-embedded breast cancer tissue sections

Diagnostic Pathology

Volumn 7, Issue 1, 2012, Pages

  Nitta, Hiroaki ^a   Kelly, Brian D ^a   Padilla, Mary ^b   Wick, Nikolaus ^a   Brunhoeber, Patrick ^a   Bai, Isaac ^a   Singh, Shalini ^a   Ranger Moore, Jim ^a   Bieniarz, Chris ^a   Tsuda, Hitoshi ^c   Grogan, Thomas M ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b Roche Tissue Diagnostics   (Spain)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Breast cancer; Dual color in situ hybridization; Gene protein assay; HER2; Immunohistochemistry

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; FIXATIVE; FORMALDEHYDE; PARAFFIN; TUMOR MARKER;

ARTICLE; BREAST TUMOR; CELL STRAIN MCF 7; CENTROMERE; CHEMISTRY; CHROMOSOME 17; EVALUATION; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LABORATORY AUTOMATION; METHODOLOGY; OBSERVER VARIATION; PREDICTIVE VALUE; REPRODUCIBILITY; TISSUE FIXATION; TISSUE MICROARRAY;

AUTOMATION, LABORATORY; BREAST NEOPLASMS; CENTROMERE; CHROMOSOMES, HUMAN, PAIR 17; FEMALE; FIXATIVES; FORMALDEHYDE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MCF-7 CELLS; OBSERVER VARIATION; PARAFFIN EMBEDDING; PREDICTIVE VALUE OF TESTS; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS; TISSUE ARRAY ANALYSIS; TISSUE FIXATION; TUMOR MARKERS, BIOLOGICAL;

EID: 84861569610     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-7-60     Document Type: Article

References (26)

1. Lee JA, Shaheen M, Walke T, Daly M. Clinical and health economic outcomes of alternative HER2 test strategies for guiding adjuvant trastuzumab therapy. Expert Rev Pharmacoecon Outcome Res 2011, 11:325-341.
2. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007, 25:118-145.
3. Madrid MA, Lo RW. Chromogenic in situ hybridization (CISH): a novel alternative in screening archival breast cancer tissue samples for HER2-2/neu status. Breast Cancer Res 2004, 6:R593-R600. 10.1186/bcr915, 549176, 15318940.
4. Sauter G, Lee J, Barlett JMS, Slamon DJ, Press MF. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 2009, 27:1324-1333.
5. Shah S, Chen B. Testing for HER2 in breast cancer: a continuing evolution. Patholog Res Int 2011, 2011:903202.
6. Dowsett M, Hanby AM, Laing R, Walker R. HER2 testing in the UK: consensus from a national consultation. J Clin Pathol 2007, 60:685-689. 10.1136/jcp.2006.044321, 1955081, 17322344.
7. Downs-Kelly E, Pettay J, Hicks D, Skacel M, Yoder B, Rybicki L, Myles J, Sreenan J, Roche P, Powell R, Hainfeld J, Grogan T, Tubbs R. Analytical validation and interobserver reproducibility of EnzMet GenePro: a second-generation bright-field metallography assay for concomitant detection of HER2 gene status and protein expression in invasive carcinoma of the breast. Am J Surg Pathol 2005, 29:1505-1511. 10.1097/01.pas.0000172294.67409.4f, 16224218.
8. Ni R, Mulligan AM, Have C, O'Malley FP. PGDS, a novel technique combining chromogenic in situ hybridization and immunohistochemistry for the assessment of ErbB2 (HER2/neu) status in breast cancer. Appl Immunohistochem Mol Morphol 2007, 15:316-324. 10.1097/01.pai.0000213138.01536.2e, 17721278.
9. Reisenbichler ES, Horton D, Rasco M, Andea A, Hameed O. Evaluation of dual immunohistochemistry and chromogenic in situ hybridization for HER2 on a single section. Am J Clin Pathol 2012, 137:102-110. 10.1309/AJCPLNHINN9O6YSF, 22180483.
10. Bunn PA, Helfrich B, Soriano AF, Franklin WA, Varella-Garcia M, Hirsch FR, Baron A, Zeng C, Chan DC. Expression of HER-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents. Clin Cancer Res 2001, 7:3239-3250.
11. Cicchetti DV, Feinstein AR. High agreement but low kappa: II. Resolving the paradoxes. J Clin Epidemiol 1990, 43:551-558. 10.1016/0895-4356(90)90159-M, 2189948.
12. Ross JS. Point: fluorescence in situ hybridization is the preferred approach over immunohistochemistry for determining HER2 status. Clin Chem 2011, 57:980-982. 10.1373/clinchem.2010.160762, 21558455.
13. Press MF, Finn RS, Cameron D, Di Leo A, Geyer CE, Villalobos IE, Santiago A, Guzman R, Gasparyan A, Ma Y, Danenberg K, Martin AM, Williams L, Oliva C, Stein S, Gagnon R, Arbushites M, Koehler MT. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and Lapatinib efficacy in women with metastatic breast cancer. Clin Cancer Res 2008, 14:7861-7870. 10.1158/1078-0432.CCR-08-1056, 19047115.
14. Tapia C, Schrmal P, Simon R, Al-Kuraya KS, Maurer R, Mirlacher M, Novotny H, Spichtin H, Mihatsch MJ, Sauter G. HER2 analysis in breast cancer: reduced immunereactivity in FISH non-informative cancer biopsies. Int J Oncol 2004, 25:1551-1557.
15. Nakhleh RE, Grimm EE, Idowu MO, Souers RJ, Fitzgibbons PL. Laboratory compliance with the American Society of Clinical Oncology/College of American Pathologists guidelines for human epidermal growth factor receptor 2 testing. Arch Pathol Lab Med 2010, 134:728-734.
16. Zarbo RJ, Hammond ME. Conference summary, Strategic Science symposium: Her-2/neu testing of breast cancer patients in clinical practice. Arch Pathol Lab Med 2003, 127:549-553.
17. Bernasconi B, Chiaravalli AM, Finzi G, Milani K, Tibiletti MG. Genetic heterogeneity in HER2 testing may influence therapy eligibility. Breast Cancer Res Treat 2012, 133:161-168. 10.1007/s10549-011-1744-3, 21901388.
18. Vance GH, Barry TS, Bloom KJ, Fitzgibbons PL, Hicks DG, Jenkins RB, Persons DL, Tubbs RR, Hammond EH. Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. Arch Pathol Lab Med 2009, 133:611-612.
19. Nitta H, Hauss-Wegrzyniak B, Lehrkamp M, Murillo AE, Gaire F, Farrell M, Walk E, Penault-Llorca F, Kurosumi M, Dietel M, Wang L, Loftus M, Pettay J, Tubbs RR, Grogan TM. Development of automated brightfield double in situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinoma and an assay performance comparison to manual dual color HER2 fluorescence in situ hybridization (FISH). Diagn Pathol 2008, 3:41. 10.1186/1746-1596-3-41, 2577627, 18945356.
20. Dabbs DJ, Klein ME, Mohsin SK, Tubbs RR, Shuai Y, Bhargava R. High false-negative rate of HER2 quantitative reverse transcription polymerase chain reaction of the Oncotype DX test: an independent quality assurance study. J Clin Oncol 2011, 29:4279-4285. 10.1200/JCO.2011.34.7963, 21990395.
21. Ignatiadis M, Sotiriou C. Should we assess HER2 status by Oncotype DX®?. Nature 2012, 9:12-14.
22. Paik S, Kim C, Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med 2008, 358:1409-1411. 10.1056/NEJMc0801440, 18367751.
23. Arena V, Pennacchia I, Carbone A, Capelli A. Fluorescent in situ hybridization for human epidermal growth factor receptor 2 assessment in breast cancer: is it applicable as a primary test?. J Clin Oncol 2009, 27:e8. 10.1200/JCO.2009.23.2249, 19470909.
24. Yamazoe Y, Roth RW, Kadlubar FF. Reactivity of benzidine diimine with DNA to form N-(deoxyguanosin-8-yl)-benzidine. Carcinogensis 1986, 7:179-182.
25. Gimmler-Luz MC, de Andrade HHR, Marafon AT. Benzidine- and diaminobenzidine-induced micronuclei in mice after intraperitoneal and oral single or multiple treatment. Brazilian J Gen 1997, 20:247-252.
26. Saito G, Matsunaga Y. Charge transfer and proton-transfer in the formation of molecular complexes. VIII. Benzidine-2,4-dinitophenol complexes. Bull Chem Soc Jpn 1974, 47:1020-1021.